Literature DB >> 6794445

Susceptibility of enterococci and Listeria monocytogenes to N-Formimidoyl thienamycin alone and in combination with an aminoglycoside.

G M Eliopoulos, R C Moellering.   

Abstract

The susceptibilities of 12 strains of enterococci and 10 stains of Listeria monocytogenes to N-formimidoyl thienamycin were determined by a standard broth dilution method. Minimal inhibitory concentrations for L. monocytogenes strains were less than 0.25 micrograms/ml. As a group, strains of Streptococcus faecium were less susceptible than Streptococcus faecalis strains, but even for the latter, the minimal inhibitory concentrations were slightly greater than those previously reported. Minimal bactericidal concentrations against all organisms were many-fold higher than the corresponding inhibitory concentrations. In time-kill studies, combinations of N-formimidoyl thienamycin with gentamicin were synergistic against (or they completely sterilized cultures of) all the enterococcal strains and nine to 10 strains of L. monocytogenes. The magnitude of killing by the combinations was comparable to that previously observed with penicillin-gentamicin combinations. N-Formimidoyl thienamycin-tobramycin combinations were synergistic against those strains of S. faecalis and L. monocytogenes tested, but not against those of S. faecium.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6794445      PMCID: PMC181523          DOI: 10.1128/AAC.19.5.789

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Listerial prosthetic valve endocarditis. Successful medical therapy.

Authors:  L D Saravolatz; K H Burch; T Madhavan; E L Quinn
Journal:  JAMA       Date:  1978-11-10       Impact factor: 56.272

2.  Antibiotic susceptibility of clinical isolates of Listeria monocytogenes.

Authors:  G L Wiggins; W L Albritton; J C Feeley
Journal:  Antimicrob Agents Chemother       Date:  1978-05       Impact factor: 5.191

3.  Synergism of penicillin and gentamicin against Listeria monocytogenes in ex vivo hemodialysis culture.

Authors:  K Mohan; R C Gordon; T C Beaman; R C Belding; D Luecke; C Edmiston; P Gerhardt
Journal:  J Infect Dis       Date:  1977-01       Impact factor: 5.226

4.  Species-specific resistance to antimocrobial synergism in Streptococcus faecium and Streptococcus faecalis.

Authors:  R C Moellering; O M Korzeniowski; M A Sande; C B Wennersten
Journal:  J Infect Dis       Date:  1979-08       Impact factor: 5.226

5.  Response to therapy in an experimental rabbit model of meningitis due to Listeria monocytogenes.

Authors:  W M Scheld; D D Fletcher; F N Fink; M A Sande
Journal:  J Infect Dis       Date:  1979-09       Impact factor: 5.226

6.  Thienamycin, a new beta-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties.

Authors:  J S Kahan; F M Kahan; R Goegelman; S A Currie; M Jackson; E O Stapley; T W Miller; A K Miller; D Hendlin; S Mochales; S Hernandez; H B Woodruff; J Birnbaum
Journal:  J Antibiot (Tokyo)       Date:  1979-01       Impact factor: 2.649

7.  Effect of protein binding on the activity of penicillins in combination with gentamicin against enterococci.

Authors:  R H Glew; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1979-01       Impact factor: 5.191

8.  Importance of medium in demonstrating penicillin tolerance by group B streptococci.

Authors:  K S Kim; R N Yoshimori; D T Imagawa; B F Anthony
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

9.  Antibiotic synergism against Listeria monocytogenes.

Authors:  R C Moellering; G Medoff; I Leech; C Wennersten; L J Kunz
Journal:  Antimicrob Agents Chemother       Date:  1972-01       Impact factor: 5.191

10.  MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities.

Authors:  H Kropp; J G Sundelof; J S Kahan; F M Kahan; J Birnbaum
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

View more
  29 in total

1.  Prediction of enterococcal imipenem susceptibility using ampicillin or penicillin MICs: more evidence for a class concept.

Authors:  R N Jones
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

2.  Influence of high-level gentamicin resistance and beta-hemolysis on susceptibility of enterococci to the bactericidal activities of ampicillin and vancomycin.

Authors:  E Cercenado; G M Eliopoulos; C B Wennersten; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

Review 3.  Screening and treatment of infections caused by resistant enterococci.

Authors:  D J Herman; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

4.  In vitro activity of cefpirome (HR810) against Enterococcus species.

Authors:  P F Wheat; R C Spencer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-03       Impact factor: 3.267

Review 5.  Antibiotic combinations: should they be tested?

Authors:  G M Eliopoulos; C T Eliopoulos
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

6.  Pharmacokinetics and bacteriological efficacy of N-formimidoyl thienamycin in experimental Escherichia coli meningitis.

Authors:  P Patamasucon; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

Review 7.  In vitro activity of imipenem--a review.

Authors:  I Braveny
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

8.  Lack of in vivo and in vitro bactericidal activity of N-formimidoyl thienamycin against enterococci.

Authors:  R Auckenthaler; W R Wilson; A J Wright; J A Washington; D T Durack; J E Geraci
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

Review 9.  Antimicrobial chemotherapy of human infection due to Listeria monocytogenes.

Authors:  E M Jones; A P MacGowan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-03       Impact factor: 3.267

Review 10.  Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  S P Clissold; P A Todd; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.